MENSTRUAL BLEEDING PATTERNS OF IMPLANON USERS
Main Article Content
Abstract
Objectives: to comment the menstrual pattern of clients who used Implanon NXT® for 3 years. Subjects and Methods: A described cohort study of 310 clients who inserted Implanon NXT® for contraception from June 2017 to May 2018, followed to May 2021 at Center for reproductive health and Family planning – National Hospital for Obstetrics and Gynaecology. Results: Amenorrhoea, normal menstrual, frequent bleeding, infrequent bleeding, and menorrhagia were reported by 38.7%, 25.2%, 7.1%, 12.2% and 17.4% clients respectively in the first 6 months, and changed to 20.2%, 37.2%, 1.4%, 22.8% and 18.4% after 3 years. Dysmenorrhea and menstrual loss were decreased signficantly (p < 0.001). The discontinuation rate of Implanon due to menstruals bleeding were 44.4%. Conclusion: Menstrual side effects is the most common side effect and that is the most frequently reported reason for discontinuation.
Article Details
Keywords
Implanon NXT®, bleeding pattern, removal
References
2. Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Human Reproduction. 11/2015 2015;30(11):2527-2538.
3. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon® on menstrual bleeding patterns. The European Journal of Contraception & Reproductive Health Care. 01/2008 2008;13(sup1):13-28.
4. Lazorwitz A, Aquilante CL, Dindinger E, Harrison M, Sheeder J, Teal S. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users. Obstetrics and gynecology. Oct 2019;134(4):807-813.
5. Parkpinyo N, Panichyawat N, Sirimai K. Early Removal of the Etonogestrel Contraceptive Implant and Associated Factors Among Users at the Urban Family Planning Clinic in Siriraj Hospital, Bangkok, Thailand. Siriraj Medical Journal. 2021-05-27 2021;73(6):399-405.
6. Weisberg E, Bateson D, McGeechan K, Mohapatra L. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system. The European Journal of Contraception & Reproductive Health Care. 02/2014 2014;19(1):5-14.
7. Aisien AO, Enosolease ME. Safety, efficacy and acceptability of implanon a single rod implantable contraceptive (etonogestrel) in University of Benin Teaching Hospital. Nigerian journal of clinical practice. Sep 2010;13(3):331-335.
8. Nguyễn Khắc Liêu. Miền ngưỡng hormon chảy máu kinh và ứng dụng trong thực tiễn. Hà Nội: Nhà xuất bản Y học; 2008.
9. Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertility and Sterility. 11/2018 2018;110(6):1129-1136.